Krishnan Nandabalan

About Krishnan Nandabalan

Krishnan Nandabalan is a chief executive officer and chairman at Invea Therapeutics.

Krishnan Nandabalan reports to the SEC as a director or major shareholder of 1 public company: BioXcel Therapeutics (BTAI).

Krishnan Nandabalan first appears on SEC filings in 2018.

Experience

This experience comes from SEC filings. The years are when the filings name Krishnan Nandabalan in the role, so the role may have started earlier or lasted longer.

Key Colleagues at Startups

The people Krishnan Nandabalan works with at each company, as listed on that company's latest Form D.

Sources

1. SECInvea Therapeutics, Inc Form D, filed Dec 10, 2025
2. SECForms 3, 4 and 5 filed by Krishnan Nandabalan (SEC filer 1733387)